Trials / Completed
CompletedNCT00569751
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 5,016 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System | Drug Eluting Stent used to treat de novo coronary artery lesions. |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2006-11-01
- Completion
- 2008-07-01
- First posted
- 2007-12-07
- Last updated
- 2008-09-29
Locations
53 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00569751. Inclusion in this directory is not an endorsement.